Signal machine
Vente groupé actif — 5 initiés distincts, $120.5M, fenêtre close le Oct 7, 2026.
Chiffres calculés à partir des déclarations réglementaires officielles — .
Analystesobjectif 27.58 USD (+50%) · consensus 4.77/5 · 13 achat · 0 conserver · 0 vente
Détentioninitiés 1.58% · institutions 110.91% · vente à découvert 24.8% du flottant
En USD · au Oct 19, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de Relay Therapeutics, Inc. uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Source des informations de marché · Oct 19, 2026
Identité selon la SEC · Oct 19, 2026
Chronologie sur le marché · historique complet
5 achats273 ventes— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail | |
|---|---|---|---|---|---|
| Patel Sanjiv | Vente | $872.4K | SEC |
| Catinazzo Thomas | Vente | $325.4K | SEC |
| Catinazzo Thomas | Vente | $4K | SEC |
| Bergstrom Donald A | Vente | $161.8K | SEC |
| Patel Sanjiv | Vente | $912.9K | SEC |
| Catinazzo Thomas | Vente | $335.6K | SEC |
| SVF Pauling (Cayman) Ltd | Vente | $116.4M | SEC |
| Rahmer Peter | Vente | $90.3K | SEC |
| Catinazzo Thomas | Vente | $349.7K | SEC |
| Patel Sanjiv | Vente | $979.9K | Taille inhabituelle | SEC |
| Rahmer Peter | Vente | $13.9K | SEC |
| Bergstrom Donald A | Vente | $41.6K | SEC |
| Catinazzo Thomas | Vente | $27.2K | SEC |
| Catinazzo Thomas | Vente | $331.1K | SEC |
| Patel Sanjiv | Vente | $943.7K | Taille inhabituelle | SEC |
| Patel Sanjiv | Attribution | $21.2K | Taille inhabituelle | SEC |
| Bergstrom Donald A | Vente | $162K | SEC |
| Rahmer Peter | Attribution | $21.2K | Taille inhabituelle | SEC |
| Rahmer Peter | Vente | $954.5K | Taille inhabituelle | SEC |
| Catinazzo Thomas | ExerciceD (dérivé) | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | SEC |
| Catinazzo Thomas | Exercice | $283.9K | Taille inhabituelle | SEC |
| Catinazzo Thomas | ExerciceD (dérivé) | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | SEC |
| Catinazzo Thomas | Vente | $1M | Taille inhabituelle | SEC |
| Catinazzo Thomas | ExerciceD (dérivé) | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | SEC |
| Bergstrom Donald A | Exercice | $385K | Taille inhabituelle | SEC |